EUVIMEDEUVIMED entdecken
Crossref

Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study

R Atreya, J O Lindsay, M Ferrante, B Siegmund, Q Cao, S van Haaren, J Crowley, T Anschutz, A Garrison, X Huang, M Dubinsky

Zeitschrift für Gastroenterologie · 01.08.2026 · 64 (08) · e316-e317

DOI: 10.1055/s-0046-1826516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.08.2026. Verfasst von R Atreya und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Atreya, R., Lindsay, J. O., Ferrante, M., Siegmund, B., Cao, Q., Haaren, S. V., Crowley, J., Anschutz, T., Garrison, A., Huang, X., & Dubinsky, M. (2026). Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study. Zeitschrift für Gastroenterologie, 64(08), e316-e317. https://doi.org/10.1055/s-0046-1826516

Vancouver

Atreya R, Lindsay JO, Ferrante M, Siegmund B, Cao Q, Haaren SV, et al. Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study. Zeitschrift für Gastroenterologie. 2026;64(08):e316-e317. doi:10.1055/s-0046-1826516

BibTeX
@article{Atreya2026,
  author = {Atreya, R and Lindsay, J O and Ferrante, M and Siegmund, B and Cao, Q and Haaren, S van and Crowley, J and Anschutz, T and Garrison, A and Huang, X and Dubinsky, M},
  title = {Durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s Disease: a post hoc analysis of part 2 of the SEQUENCE study},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2026},
  volume = {64},
  number = {08},
  pages = {e316--e317},
  doi = {10.1055/s-0046-1826516}
}
Kostenlos starten →